HCPLive Network

Flu Vaccine Approved

The FDA announced last week that it had approved the formulation of the 2011-2012 influenza vaccine for the six manufacturers that are licensed to produce and distribute it in the US.
 
Each year, the vaccine contains the three virus strains determined to be those likely to cause the most illness during the upcoming flu season. This year’s vaccine includes the same three strains as last year’s, though those who received the vaccine last year should not be tempted to skip this year’s.
 
“It is important to get vaccinated every year, even if the strains in the vaccine do not change, because the protection received the previous year will diminish over time and may be too low to provide protection into the next year,” said Karen Midthun, MD, director of FDA’s Center for Biologics Evaluation and Research, in a press release.
 
The brand names and manufacturers of vaccine for the upcoming flu season are: Afluria (CSL Limited); Fluarix (GlaxoSmithKline Biologicals); FluLaval (ID Biomedical Corporation); FluMist (MedImmune Vaccines Inc.); Fluvirin (Novartis Vaccines and Diagnostics Limited); and Fluzone, Fluzone High-Dose, and Fluzone Intradermal (Sanofi Pasteur Inc.). (Fluzone Intradermal is delivered via a very small needle into the skin rather than muscle and is available for those aged 18 to 64.)
 
Around the Web
 
FDA approves vaccines for the 2011-2012 influenza season [FDA] 


Further Reading
Research indicates that patients with type 2 diabetics mellitus and low testosterone levels are 6 times more likely than those with normal testosterone levels to have increased carotid artery intima media thickness (CIMT) and decreased endothelial function.
Distal radius fracture—also called a wrist fracture by patients—is common. Its incidence is expected to increase in the next 20 years, since our population is aging and the risk of this specific fracture increases in patients with metabolic disorders, including osteoporosis. However, the health care community has yet to reach a consensus regarding indications for surgery, and there is insufficient data to identify a preferred operative technique.
Team-based feedback has the potential to improve surgeons’ relationships with coworkers and patients. The clinical implication: using such feedback to improve less-than-optimal behaviors could increase practice reimbursement under the “pay-for-professionalism” system.
More Reading